The influence of coronavirus disease-2019 (COVID-19) on Parkinson’s disease: An updated systematic review by Jaiswal, Vikash et al.
eCommons@AKU 
Department of Paediatrics and Child Health Division of Woman and Child Health 
1-1-2021 
The influence of coronavirus disease-2019 (COVID-19) on 
Parkinson’s disease: An updated systematic review 
Vikash Jaiswal 
Research & Academic Affairs, Larkin Health System, South Miami, USA. 
Danah Alquraish 
Research & Academic Affairs, Larkin Health System, South Miami, USA. 
Zouina Sarfraz 
Research & Academic Affairs, Larkin Health System, South Miami, USA. 
Azza Sarfraz 
Aga Khan University, azza.sarfraz@aku.edu 
Shavy Nagpal 
The Research Institute of St. Joe's Hamilton, Hamilton, Canada 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr 
 Part of the Community Health and Preventive Medicine Commons, Nervous System Diseases 
Commons, Neurology Commons, Pediatrics Commons, Primary Care Commons, and the Virus Diseases 
Commons 
Recommended Citation 
Jaiswal, V., Alquraish, D., Sarfraz, Z., Sarfraz, A., Nagpal, S., Shrestha, P. S., Mukherjee, D., Guntipalli, P., 
Sánchez Velazco, D. F., Bhatnagar, A. (2021). The influence of coronavirus disease-2019 (COVID-19) on 
Parkinson’s disease: An updated systematic review. Journal of Primary Care & Community Health, 12. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/1085 
Authors 
Vikash Jaiswal, Danah Alquraish, Zouina Sarfraz, Azza Sarfraz, Shavy Nagpal, Prakriti Singh Shrestha, 
Dattatreya Mukherjee, Prathima Guntipalli, Diana F. Sánchez Velazco, and Arushee Bhatnagar 
This article is available at eCommons@AKU: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr/1085 
https://doi.org/10.1177/21501327211039709
Journal of Primary Care & Community Health
Volume 12: 1–9 
© The Author(s) 2021
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI  10.1177/2 50132721103970
journals.sagepub.com/home/jpc
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, 




At the onset of the coronavirus disease (2019) pandemic on 31 
December 2019, many reports found that SARS-CoV-2 pri-
marily caused pneumonia-like symptoms.1 This virus emerged 
as a global threat and a public health emergency of imminent 
concern across countries worldwide, with exponential trans-
mission capability. As of May 25, 2021, there have been 
167 million confirmed cases of COVID-19, with reported 
deaths up to 3.47 million globally.2 COVID-19 belongs to a 
novel member of the coronaviridae family named SARS-
CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).3 
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Abstract
Background: COVID-19 has affected global communities with multiple neurological complications in addition to other 
critical medical issues. COVID-19 binds to the host’s angiotensin-converting enzyme 2 (ACE2) receptors, which are 
expressed in the neurons and glial cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors 
are abundantly expressed on dopamine neurons, which may worsen the prognosis of motor symptoms in Parkinson’s 
disease (PD). SARS-CoV-2 may lead to an indirect response via immune-mediated cytokine storms and propagate through 
the CNS leading to damage. In this systematic review, we aim to provide thorough analyses of associations between 
COVID-19 and neurological outcomes for patients with PD. Methods: Using PRISMA statement 2020, a systematic review 
was conducted to isolate confirmed COVID-19 patients and analyze the PD-associated neurological outcomes using the 
following databases: PubMed, Science Direct, Google Scholar, and Cochrane databases. The following keywords were used 
“COVID19, SARS-CoV-2, Parkinson’s disease, Pandemic, Mortality.” A modified Delphi process was employed. Results: 
Of the 355 studies located during the initial round of screening, 16 were included in the final synthesis. Of PD patients 
who tested positive for SARS-CoV-2, worsening motor symptoms and other viral-associated symptoms were reported. 
These symptoms included bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and 
legs. Encephalopathy was presented in 2 of the included studies. Increased mortality rates were identified for hospitalized 
patients due to COVID-19 and PD as compared to other patient groups. Conclusion: Patients with PD may experience 
substantial worsening of symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical studies 
in the future ought to explore the disease severity and neurological outcomes in COVID-19 positive patients with PD as 
compared to non-PD patients, in addition to understanding the role of ACE2 in increased vulnerability to contracting the 
infection and as a treatment modality.
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Coronaviruses are enveloped positive single-stranded RNA 
viruses, and the 3′ terminal contains structural proteins. The 
Spike (S) protein allows the virus to fuse to host cell mem-
branes in proximity to infected and uninfected cells.4 A surge 
in the levels of cytokines (TNF-α, IL-6, IL-8, and IL-10) have 
been reported, leading to a suppression of T-cell response.5 To 
date, a multitude of studies have assessed the role of angioten-
sin-converting enzyme 2 (ACE2) receptors in the increasing 
vulnerability of hosts, however, there is a dearth of analysis on 
the role of ACE inhibitors in treating Parkinson’s disease (PD) 
patients. A meta-analytical study found that PD is a common 
comorbidity in older patients with COVID-19, which is also 
associated with poor in-hospital outcomes.6 The results of the 
meta-regression further consolidated that mortality from 
COVID-19 was statistically associated with age, and not with 
gender or dementia, which is key in monitoring PD to mini-
mize infection risks and prevent adverse events.6 In this sys-
tematic review, we aim to provide an updated, thorough 
analysis of associations between COVID-19 and neurological 
outcomes for patients with PD.
Coronavirus disease (2019) has prompted many chal-
lenges in global healthcare systems due to its unpredictability 
and unique manifestations in (1) pulmonary, (2) neurological, 
(3) cardiovascular, (4) gastrointestinal, and (5) hematological 
systems. The scientific literature confirms the presence of 
SARS-CoV-2 in CSF, in addition to respiratory, fecal, and 
blood samples. In about 36.4% of cases, neurological find-
ings have been identified, ranging from dizziness, headache, 
hyposmia, hypogeusia, dysphagia, muscle pain, seizures, and 
loss of consciousness.7 COVID-19 also influences socializ-
ing factors such as the surge in isolation-induced neurologi-
cal effects, limited social activities possibly leading to short 
or long-term neuropsychiatric disorders.
We hypothesize that COVID-19 induced lockdowns, 
self-isolation, and the fears associated with contracting dis-
ease accentuate neuro-psychiatric problems such as depres-
sion and cognition. Figure 1 illustrates motor and non-motor 
manifestations in addition to autonomic manifestations that 
are pertinent in the assessment of the clinical outcomes of 
confirmed positive PD patients. Given the dearth of data, 
we aim to provide a comprehensive and updated systematic 
review to guide clinical care and practice in understanding 
the effects of COVID-19 on Parkinson’s disease.
Methodology
Using the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) 2020 statement, a system-
atic literature search was performed from December 2019 
through May 2021.8 The following set of keywords were 
used, employing the Boolean (and/or) logic: “COVID19,” 
“SARS-CoV-2,” “Parkinson’s disease,” “Pandemic,” 
“Mortality.” We searched the following databases, namely, 
PubMed, Cochrane, Science Direct, EMBASE, and Google 
Scholar. A modified Delphi approach was utilized to include 
studies and ensure that the clinical outcome measures are 
identified in a systematic and unanimous order in the 
included studies.9 The a-priori Delphi process for system-
atically analyzing the available data involved 2 rounds of 
screening with a final panel feedback round.9 During round 
1, 10 questions pertaining to PD and clinical outcome mea-
sures were identified using a pre-determined panel of 
experts, which was graded on a Likert scale (1-5). In round 
2, the top 5 questions were sent to the panel and they were 
individually scored by all members. In the panel feedback 
round, the prioritized research questions with the final list 
and scores were sent to the panel for information sharing. 
The PRISMA flowchart is illustrated in Figure 2.
Study Selection
We included studies with confirmed COVID-19 disease 
who had a history of Parkinson’s disease. Studies published 
with open access availability were included. In total, 355 





Figure 1. Clinical manifestations of Parkinson’s disease.
Jaiswal et al 3
studies were located during the initial round of screening. 
During this round of screening, all authors scanned the 
abstracts and titles independently, which led to the location 
of 155 studies. In the second screening round, full-text stud-
ies were screened, and 125 articles that met the exclusion 
criteria were removed. During the third screening round, 84 
studies were screened for eligibility. In total, 35 studies 
were excluded as non-PD patient groups were present, 16 
studies had incomplete data for sourcing, and 16 of the full-
text studies present with post-COVID-19 PD development, 
which met the exclusion criteria. Finally, 16 studies were 
included in the qualitative synthesis.
Eligibility Criteria
The inclusion criteria for studies and the target population 
consisted of (1) COVID-19 patients with Parkinson’s dis-
ease, (2) patients diagnosed with Parkinson’s disease before 
COVID-19 infection, (3) age group >21 years old, (4) male 
and/or female, and (5) available articles in English language 
only. Studies were excluded if they met 1 or more of the 
following criteria (1) COVID-19 negative PD patients, (2) 
studies on pregnant women, (3) the pediatric population, (4) 
crossover study design, and (5) commentaries/perspective 
pieces.
Figure 2. PRISMA Flowchart.
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Data Extraction and Synthesis
The following data were extracted from eligible studies: 
serial number, author and year, study design, sample size, 
gender, age, comorbidities, disease duration, PD outcomes, 
COVID-19 associated symptoms. A shared spreadsheet was 
used to input data, which was extracted independently by 3 
authors for analysis and cumulative result interpretation 
(V.J., D.A., Z.S.). The fourth reviewer (A.S.) solved any 
discrepancies in data extraction and reach a consensus in 
case of any disagreements.
Quality assessment was conducted by 2 authors (V.J. and 
Z.S.), who independently assessed the (1) criteria of diagnosis 
of COVID-19 patients, (2) confirmed diagnosis of PD before 
the COVID-19 pandemic, (3) PD sequelae in the included 
studies. A descriptive analysis was conducted and presented 
for the included studies. Percentages and means were pre-
sented. Frequent outcomes were reported if they have a fre-
quency of at least 5% or more in the included studies. The 
term PD complications were based on the motor, non-motor, 
and autonomic complications mentioned in Figure 1.
No funding was obtained for this study.
Results
Of the 355 studies identified during the first round of 
screening, 16 studies comprising, 7 (43.8%) were case 
reports and case series, 4 (25%) case-control studies, 2 
(12.5%) cross-sectional, 2 (12.5%) cohort, and 1 (6.25%) 
retrospective study were added (Figure 3).10-25 In total, a 
synthesis of 1290 PD patients with COVID-19 and the char-
acteristics of all included studies are presented in Table 1.
Male gender was predominant in 10 studies,10-19 and 
female gender was the predominant 1 in 6 studies.18,20-24  
Of the available patient data, the cumulative mean of 
age in years of included patients was 76.9 years. The aver-
age disease duration spanned 11 years before the incidence 
of COVID-19 disease. Majority of the included patients 
presented with comorbid conditions, comprising of 
hypertension,10,14,16,17,21,22,24,25 diabetes,11,13,17,19-22 obesity,10 
dyslipidemia,22 cardiovascular disease,10,11,15,16,20-22,25 
immunocompromised,10,16,25 COPD,10,14,15,19 asthma,19 
chronic renal, and liver diseases.19,20,25 Of the PD patients 
that were tested and positive infection with SARS-CoV-2, 
worsening of motor symptoms10-12,15-17,19,20,22,24 including 
bradykinesia, tremors, gait disturbances, delirium, and 
dementia14,20 were noted; severe spasms of the arms and 
legs23 were found, with individual study percentages of 
motor symptoms ranging from 19% to 100%, along with 
other COVD-19 symptoms. Encephalopathy was also one 
of the major symptoms, which presented in 2 (12.5%) of 
the 16 studies.20,24 Mortality rates for PD patients with 
COVID-19 who were hospitalized ranged from 5.7% to 
100%.10-17,19-23,25
Discussion
To our best understanding, this is the first systematic review 
to assess clinical outcomes of Parkinson’s disease (PD) in 
confirmed COVID-19 patients with a pre-pandemic PD 
diagnosis. Wide varieties of neurological consequences have 
been reported in scientific literature among COVID-19 posi-
tive patients.26-34 Neurological symptoms comprised of the 
following include those associated with core dysfunction 
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(fatigue, headache, confusion, stroke,35 dizziness, syncope,36 
seizure, anorexia, and insomnia),37-39 central-peripheral mix-
ture (Guillain Barre syndrome),40 enteric, or peripheral ner-
vous systems dysfunction (anosmia, ageusia, myoclonus,41 
neuropathic pain, and myalgia).42 The increase in hospital 
admission and mortality rates in PD and other chronic neu-
rological diseases during the COVID-19 pandemic is of 
imminent concern as the long-term sequelae are currently 
undetermined. Most neurological diseases, including PD, 
are dose-dependent on prescribed medications for symptom-
atic management. With the compounded neuropsychiatric 
symptoms due to social isolation and outpatient clinics, tem-
porarily being suspended and irregular visits, these are caus-
ative in worsening PD symptoms among COVID-19 
patients.43
In this systematic review, we included studies with 
COVID-19 positive patients with a prior history of 
Parkinson’s disease. The most common manifestations due 
to COVID-19 in PD patients were found to be motor dys-
function. The majority of the studies showed a common 
motor deficit domain in the range of moderate to severe. 
Some of the patients presented with delirium, dementia, and 
encephalopathy among other COVID-19 complications. 
We posit that this may be related to the ACE2 mechanism in 
the nervous system. It is postulated that SARS-CoV-2 enters 
the cell, increases the activity of T cells, causing vasodila-
tion, thrombosis, and hypoxemia, which may then lead to 
stroke and seizures. One theory supports the effect of the 
virus by stating that SARS-COV-2 attacks ACE 2 receptors 
in a multi-organ manner, targeting the brain. A study found 
that ACE2 receptors act locks on cells and the SARS-CoV-2 
spike proteins act rapidly multiply on entering the cells. 
These ACE2 receptors control tissues in the eye, reproduc-
tive system, renal-excretory, digestive, and respiratory sys-
tem, and 21 different regions of the brain, which require 
further deliberation in PD patients.44
We found that the average age of all participants was 
76.9 years with a male predominance, in addition to a prior 
disease duration of 11 years. The majority of the patients 
reported the presence of other comorbidities, of which the 
following were the most common: hypertension, diabetes, 
obesity, dyslipidemia, cardiovascular disease, immunocom-
promised, COPD, asthma, chronic renal, and chronic liver 
diseases. Documented COVID-19 neurological complica-
tions include stroke, especially in younger patients, reflect-
ing the hypercoagulable state, leukoencephalopathy, and 
hemorrhagic leukoencephalopathy. Although direct enceph-
alitis was documented, it is rare but does occur. Further, cra-
nial neuropathies are also infrequent but include the loss of 
sense of smell (cranial nerve 1) and Bell’s palsy (cranial 
nerve 7).45 There have been neurocognitive signs, particu-
larly in older age groups that warrant further associations to 
PD symptoms, clinical care, and management in the short 
and long term.
The COVID-19 pandemic has led to adaptive changes to 
acute PD care. A majority of multidisciplinary care is per-
formed remotely, and the reallocation of resources has taken 
place in an ad hoc fashion across many centers.46 The acute 
care of PD has been facilitated using telemedicine, albeit 
with certain limitations such as remotely assessing mood 
and anxiety, cognition, postural reflexes, and rigidity.46 
Other adaptive strategies in treating acute PD during the 
COVID-19 pandemic include remote deep brain stimula-
tion (DBS) programming-based tools that may evaluate 
patient symptoms online, which have shown to improve the 
motor symptoms among PD patients during quarantine.46 
The signs and symptoms of COVID-19 in patients with PD 
may appear 2 to 14 days post-exposure, and without any 
cure, the several FDA approved vaccines may protect from 
hospitalization or severe illness. In the United States, 
BioNTech/Pfizer, Johnson & Johnson’s, and Moderna have 
been widely distributed in the event of viral exposure.47 
Data also shows that the vaccines are safe and beneficial to 
patients with Parkinson’s disease. While patients with PD 
may experience side effects such as temporary worsening of 
pre-existing Parkinson’s symptoms, vaccines are believed 
to not cause any long-term changes to PD signs and symp-
toms.47 To improve compliance to life post-COVID-19, it is 
essential that adapting to life with PD and viral infection 
incorporates daily hygiene measures. Symptoms such as 
altered speech, poor balance, restlessness, and fatigue may 
lead to poor adherence to daily hygiene. Through PD tai-
lored home equipment, adjustments, and routine habit inte-
gration, patients may be able to manage the disease well 
during and post the COVID-19 pandemic.
Limitations
We had certain limitations. The first included the presence 
of confounder factors. These related to the finding that mul-
tiple studies of patients with elderly PD patients had other 
comorbidities, possibly leading to an overrepresentation of 
findings. Secondly, the duration of PD and the severity of 
the pre-pandemic symptoms possibly influenced the syn-
thesis of clinical outcomes due to COVID-19 infection. 
Thirdly, pertinent information, including prior and current 
medications and compliance to treatment was lacking, lead-
ing to a lack of generalized recommendations for PD and 
COVID-19 clinical care. Albeit, our findings are pertinent 
for long-term PD patients with acquired COVID-19 
infection.
Conclusion
COVID-19 has a peaked mortality rate in older age groups, 
compounded with comorbid conditions. The CNS is 
increasingly susceptible to SARS-CoV-2, deteriorating 
neurological findings, particularly in patients with PD. We 
8 Journal of Primary Care & Community Health 
find that motor dysfunction, delirium, dementia, severe 
spasms of arms and legs, and encephalopathy are pertinent 
clinical findings in PD patients and ought to be addressed in 
current care and practice. The susceptible groups of 
COVID-19 positive patients with a history of PD are elderly 
males with 10 years or longer duration of illness and other 
comorbid conditions. It is still unclear how SARS-CoV2 
affects the long-term health of the nervous system in PD 
patients. It is recommended that healthcare practitioners 
address diminished neurological outcomes, changes in-hos-
pital stay, and raised mortality in PD patients.
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